1.15
+0.0099(+0.87%)
Currency In USD
| Previous Close | 1.14 |
| Open | 1.13 |
| Day High | 1.16 |
| Day Low | 1.12 |
| 52-Week High | 3.12 |
| 52-Week Low | 0.77 |
| Volume | 14,583 |
| Average Volume | 222,865 |
| Market Cap | 95.02M |
| PE | -3.11 |
| EPS | -0.37 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 1.56 |
| Change | 0.01 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $307.36 as of May 09, 2025 at a share price of $1.15. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $558.25 as of May 09, 2025 at a share price of $1.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Newsfile
Apr 29, 2025 11:27 AM GMT
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a cl
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Newsfile
Apr 16, 2025 11:27 AM GMT
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAV
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Newsfile
Apr 01, 2025 11:27 AM GMT
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment